| ¡ Regístrese ahora en R3i! BM Everett, AD Pradhan, DH Solomon, N Paynter, J Macfadyen, ... | | |
| ¡ Regístrese ahora en R3i! PM Ridker, P Libby, JG MacFadyen | | |
| † Evaluating the Residual Risk of Recurrent Cardiovascular Events in Contemporary Cardiovascular Outcomes Trials K Serge, Y Daaboul, D Bhatt, PM Ridker, RW Yeh, R Mehran, S Baron, ... Journal of Clinical Lipidology 17 (4), e1-e2, 2023 | | 2023 |
| 10 Biomarkers and Use in Precision Medicine P LIBBY, PM RIDKER | | |
| 1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function M Gorski, PJ Van Der Most, A Teumer, AY Chu, M Li, V Mijatovic, IM Nolte, ... Scientific reports 7 (1), 45040, 2017 | 134 | 2017 |
| 1071 PLASMA PENTRAXIN 3 LEVELS REFLECT METABOLIC SYNDROME IN PATIENTS WITH CORONARY ARTERY DISEASE T Miyazaki, S Chiuve, F Sacks, P Ridker, P Libby, M Sagara, M Aikawa Atherosclerosis Supplements 10 (2), e420-e421, 2009 | | 2009 |
| 13-OR: Effects of Randomized Statin Therapy vs. Placebo on Plasma Branched-Chain Amino Acids (BCAAs) and Type 2 Diabetes (T2D) Risk: Secondary Analysis of the JUPITER Trial DK Tobias, P Ridker, R Glynn, S Mora Diabetes 70 (Supplement_1), 2021 | | 2021 |
| 13■ Inflammation in the Development and Complications of Coronary Artery Disease T Ahmad, P Ridker Cardiac Biomarkers in Clinical Practice, 273, 2009 | | 2009 |
| 16 C-Reactive Protein as a Tool for Risk SS Bassuk, PM Ridker Cardiovascular Biomarkers: Pathophysiology and Disease Management, 237, 2010 | | 2010 |
| 20th Annual Massimo Calabresi Lectureship: CRP, Statin Therapy and... PM Ridker MedMedia Services, Yale University School of Medicine, 2009 | | 2009 |
| 2153 The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease; a cohort study CC Van'T Klooster, PM Ridker, J Hjortnaes, Y Van Der Graaf, ... European Heart Journal 40 (Supplement_1), ehz748. 0088, 2019 | | 2019 |
| 2417 Elevated interleukin-6 and interleukin-18 concentrations predict residual inflammatory risk both before and after interleukin-1beta inhibition with canakinumab PM Ridker, J MacFadyen, T Thuren, P Libby European Heart Journal 40 (Supplement_1), ehz748. 0165, 2019 | | 2019 |
| 3. Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men PM Ridker, M Cushman, MJ Stampfer N Engl J Med 336, 973-9, 1997 | 51 | 1997 |
| 31 Evolving Targets of Therapy: Inflammation as and Prevent Cardiovascular Events PM Ridker Clinical Lipidology: A Companion to Braunwald's Heart Disease, 358, 2014 | | 2014 |
| 32.5 Arterielle Thromboembolien an seltenen Lokalisationen PM Ridker, MJ Stampfer, N Rifai, V Salomaa, C Matei, N Aleksic, ... 32 Arterielle Thromboembolien, 507, 0 | | |
| 358 Understanding and mitigating the risk of infection with canakinumab P Libby, R Glynn, T Thuren, R Hilkert, P Ridker European Heart Journal 39 (suppl_1), ehy564. 358, 2018 | 1 | 2018 |
| 652 Blood pressure, C-reactive protein, and risk of future cardiovascular events: a prospective study among 15,215 women GJ Blake, N Rifai, JE Buring, PM Ridker European Heart Journal 5 (24), 116, 2003 | | 2003 |
| 696 Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double blind, placebo-controlled trial K Reynolds, M Mooradian, D Zlotoff, P Ridker, T Neilan, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 4* | 2022 |
| 858-4 C-reactive protein levels and race/ethnicity MA Albert, RJ Glynn, J Buring, PM Ridker Journal of the American College of Cardiology 43 (5S2), A524-A524, 2004 | | 2004 |
| 87. The Physicians' Health Study: prospective evaluations of tPA and PAI-1 PM Ridker Fibrinolysis and Proteolysis, 27, 1996 | | 1996 |
